Type 2 Diabetes & Low Testosterone
Hypogonadism in T2D and the T4DM / TIMES2 testosterone-for-diabetes question
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not an FDA indication (testosterone is NOT approved to prevent or treat diabetes)
Reference only. Not medical advice.
What can go wrong
The key risk is mis-framing: treating a downstream marker (low T) instead of the cardiometabolic disease driving it. Where testosterone is used, T4DM's hematocrit signal (elevations >54%) flags real erythrocytosis/thromboembolic risk that scales with dose and duration, and exogenous testosterone suppresses endogenous production and fertility. Testosterone is not FDA-approved to prevent or treat diabetes; using it for that is off-label and unproven for hard outcomes.
This is something to take to a clinician. The Atlas can tell you what is known about type 2 diabetes & low testosterone in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Low total testosterone is found in a large fraction of men with type 2 diabetes (T2D) - cross-sectional studies repeatedly report that roughly a third to half of men with T2D have testosterone in the hypogonadal range, much of it driven by obesity-related suppression of the hypothalamic-pituitary-gonadal axis and by low sex hormone-binding globulin (SHBG). The landmark T4DM trial (Wittert et al., Lancet Diabetes & Endocrinology, 2021) tested whether giving testosterone could prevent diabetes. It is a textbook case of an impressive statistic that did NOT change practice: a 40% relative reduction in 2-year diabetes incidence, yet no regulatory indication and explicit guidance that testosterone is not a substitute for lifestyle change.
Low T in diabetic men is one of medicine's most reproducible associations - but a 40% diabetes reduction did not earn an indication.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Two threads converge. First, adipose tissue raises aromatase activity and inflammatory tone, and central obesity plus hyperinsulinemia suppress GnRH/LH pulsatility - producing a functional, often reversible secondary hypogonadism. Second, insulin resistance lowers SHBG, which mechanically drops TOTAL testosterone (less carrier protein) even when free testosterone may be less affected - a measurement artifact that inflates apparent 'low T' rates if only total T is read. Conversely, low testosterone may worsen insulin sensitivity by reducing lean mass and favoring fat gain, giving a plausible bidirectional loop. T4DM's mechanistic readouts suggested testosterone's diabetes effect tracked with reduced fat mass and increased muscle, not a unique glycemic drug action.
Why a 40% reduction did not become a prescription
T4DM (n=1007, men >=50, waist >=95 cm, impaired glucose tolerance or new T2D, all in a lifestyle program) randomized intramuscular testosterone undecanoate vs placebo for 2 years. At 2 years, T2D (by OGTT) was present in 12.4% of the testosterone arm vs 21.0% of placebo - a ~40% relative reduction. So why no indication? Because: (1) it was a 2-year surrogate-outcome trial, not a cardiovascular or hard-outcome trial; (2) the testosterone arm showed more frequent hematocrit elevations >54%, a known thromboembolic/erythrocytosis safety signal that scales with dose and duration; (3) the authors and accompanying commentary stressed that testosterone is NOT a replacement for weight loss and lifestyle intervention, which carry their own benefits without the risks; and (4) durability beyond 2 years and rebound on stopping were unknown. The earlier TIMES2 study (Jones et al., 2011) showed modest insulin-sensitivity improvement in hypogonadal men with T2D/metabolic syndrome on transdermal testosterone, but it was smaller and shorter. The honest summary: a real, reproducible signal, deliberately not translated into 'prescribe testosterone to prevent diabetes.'
What people get wrong
Often saidDiabetic men have low T, so testosterone treats diabetes
ActuallyT4DM showed a 40% relative reduction in 2-year diabetes incidence, but this did NOT earn an FDA indication. The trial authors explicitly stated testosterone is not a substitute for weight loss and lifestyle change, and there was a hematocrit safety signal. Association and a 2-year surrogate win are not the same as an approved treatment.
Often saidA low total testosterone result confirms hypogonadism in a diabetic man
ActuallyInsulin resistance lowers SHBG, which drops TOTAL testosterone for measurement reasons even when free testosterone is closer to normal. Diabetic men specifically need free or calculated free T interpreted in context, not a single total reading.
Who profits, and who pushes back
Gary Wittert
Has repeatedly stressed that testosterone is not a replacement for lifestyle intervention and that T4DM does not support prescribing testosterone to prevent diabetes.
What we do not know
- Does the T4DM diabetes benefit persist after testosterone is stopped, or does it rebound?
- How much of the effect is simply the fat-loss/muscle-gain of any anabolic, achievable by other means?
- Would a hard-outcome (cardiovascular, mortality) trial in this population justify the hematocrit risk?
At a glance
- Low T prevalence in T2D
- Frequently cited around one third to one half of men, definition-dependent
- Dominant mechanism
- Obesity-driven functional secondary hypogonadism + low SHBG
- T4DM headline
- T2D at 2 yr: 12.4% (T) vs 21.0% (placebo)
- Indication earned
- None - testosterone is not approved for diabetes
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Type 2 Diabetes & Low Testosterone. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
T4DM (Wittert et al.)2021
Testosterone undecanoate + lifestyle cut 2-year T2D incidence to 12.4% vs 21.0% placebo (~40% relative reduction); more hematocrit elevations; authors say it is NOT a lifestyle substitute
TIMES2 (Jones et al., Diabetes Care)2011
Transdermal testosterone improved HOMA-IR/insulin sensitivity modestly in hypogonadal men with T2D or metabolic syndrome over 6-12 months
EMAS cross-sectional data2010s
Confirmed obesity and metabolic syndrome as the strongest correlates of low testosterone in community-dwelling European men